Manufacturing

Articles

Celularity and Oncternal’s collaboration will focus on therapeutics targeting Orphan Receptor 1, which is linked to aggression and survival in solid tumor cells.

Celularity and Oncternal Therapeutics to Research Placental-Derived Cellular Therapies

Novartis’ acquisition of Arctos Medical could lead to significant advancements in optogenetic therapies for patients with vision loss.

Novartis Acquires Arctos Medical, Expanding Optogenetics Profile

AGC Biologics is expanding manufacturing capacity at its Heidelberg, Germany, facility for plasmid DNA and messenger RNA.

AGC Bio Boosts Manufacturing Capacity for pDNA and mRNA at Heidelberg Facility

Nirupama (Rupa) Pike, PhD, is director of Enterprise Science and Innovation Partnerships at Thermo Fisher Scientific.

The industry considers applying automation and digitalization lessons learned during the COVID-19 pandemic to enhance workflows. 

Reevaluating Cell and Gene Therapy Development

Corning’s new Ascent fixed bed reactor (FBR) system is an automated bioproduction platform designed to significantly improve yields and reduce bioproduction costs.

Corning’s New Cell and Gene Therapy Platform Demonstrates Large-Scale Bioproduction

AGC Biologics has acquired Novartis’ Longmont, Colorado, manufacturing facility for the commercial production of cell and gene therapies.

AGC Biologics Acquires Cell and Gene Therapy Commercial Manufacturing Facility

The University of Sheffield has launched an innovative gene therapy program that could pave the way for novel treatments for neurodegenerative diseases.

University of Sheffield and CGT Catapult Launch Innovative Gene Therapy Program

Cynthia A. Challener, PhD, is a contributing editor to BioPharm International.

The benefits of single-use technologies for upstream viral-vector processes clearly outweigh their disadvantages. 

Single-Use Technologies Prove Effective for Viral Vector Process Development

PerkinElmer has entered into an agreement to acquire BioLegend, a global developer and manufacturer, in a deal valued at $5.25 billion.

PerkinElmer to Acquire BioLegend in $5.25-Billion Deal

Pall has secured a manufacturing contract with Exothera for the suspension-based manufacture of gene therapies and viral vector-based vaccines.

Manufacturing, Gene Therapies